Fig. 4: Molecular adaptations in nucleus accumbens differ across genotype following abstinence from fentanyl self-administration.
From: A Drd1-cre mouse line with nucleus accumbens gene dysregulation exhibits blunted fentanyl seeking
A Experimental timeline. Following recovery from jugular vein catheter surgery, mice underwent 5 days of fentanyl self-administration under fixed ratio 1 (FR1), followed by 5 days under FR2. Following 14 days of homecage abstinence, mice underwent a non-reinforced seeking test, then nucleus accumbens tissue was collected ~4 h later. Fold change mRNA relative to experimentally naïve male and female wildtype mice (dashed line; wildtype n = 6♀, 6♂; Drd1-cre120Mxu n = 5♀, 4♂). B Dopamine D1 receptor, Sex x Drug Interaction, p = 0.0087; ***p = 0.0005, ****p < 0.0001, wildtype vs. Drd1-cre females, males, respectively, Sidak’s post-hoc. C Preprotachykinin-1, **p = 0.0021, main effect of genotype. D Preproenkephalin, ****p < 0.0001, main effect of genotype. E Adenosine A2a, Sex x Drug Interaction, p = 0.044; **p = 0.0018, wildtype vs. Drd1-cre males, Sidak’s post-hoc. F G protein-coupled receptor 6, ***p = 0.001, main effect of genotype. G Dopamine and cAMP-regulated phosphoprotein (DARPP-32), ****p < 0.0001, main effect of genotype. H Mu opioid receptor, *p = 0.041, main effect of genotype. I Opioid related nociceptin receptor 1, ****p < 0.0001, main effect of genotype. J Delta opioid receptor, **p = 0.005, main effect of genotype. K Tropomyosin receptor kinase B (TrkB) receptor, **** p < 0.0001, main effect of genotype. L NMDA receptor Subunit 2 A, ****p < 0.0001, main effect of genotype. M NMDAR Subunit 2B, ****p’s<0.0001, wildtype vs. Drd1-cre females, males, respectively, Sidak’s post-hoc. Data are presented as mean ± SEM with individual mice overlaid.
